Exhibit 99.1 SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In ...

SIGA Technologies, Inc. (NASDAQ:SIGA) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Phillip Louis Gomez - Chief Executive Officer Dennis Hruby - Executive Vice President and Chief Scientific Officer Jay Varma - Executive Vice President and Chief Medical Officer Daniel Luckshire - Executive Vice President and Chief Financial Officer Conference Call Participants Pooya Hemami - Edison Group Paul Saunders - Hatch Capital Operator Welcome to the SIGA business update call. Befo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaw ...

财务数据和关键指标变化 - 2023年上半年公司收入约为1400万美元,其中约700万美元来自产品销售和支持活动,约700万美元来自研发活动 [18] - 2023年第二季度公司收入约为600万美元,其中约100万美元来自向国际客户销售口服TPOXX,约500万美元来自研发活动 [18] - 2023年上半年公司税前经营亏损约700万美元 [19] - 2023年第二季度公司税前经营亏损约500万美元 [19] - 2023年上半年公司净亏损约400万美元,每股摊薄亏损0.05美元 [20] - 2023年第二季度公司净亏损约300万美元,每股摊薄亏损0.04美元 [20] - 2023年6月30日公司现金余额约7600万美元 [20] 各条业务线数据和关键指标变化 - 2023年上半年约500万美元收入来自向美国国防部的产品销售 [19] 各个市场数据和关键指标变化 - 2023年第二季度公司向一个新客户进行了国际口服TPOXX销售 [18] - 公司正在积极拓展国际市场,已有一些国家进行了后续订单 [36][37] 公司战略和发展方向及行业竞争 - 公司正在推进PEP适应症的开发,这可能为扩大TPOXX储备提供科学和监管支持 [26] - 公司正在与美国政府就TPOXX的长期SNS合同进行讨论,以确保适当的储备规模和平滑的年度交付 [27] - 公司正在努力拓展客户群,使收入来源更加多元化 [25][26] - 公司CEO正在退休,董事会正在进行CEO的继任搜索 [28] 管理层对经营环境和未来前景的评论 - 尽管最近Mpox疫情有所缓解,但未来仍可能持续存在,突出了TPOXX在治疗正痘病毒方面的长期重要性 [24] - 公司相信在未来几年内,美国和其他国家将不可避免地需要使用TPOXX来应对Mpox病例 [16] 其他重要信息 - 公司已完成PEP适应症扩展试验的安全性研究,未发现任何药物相关的严重不良事件 [8] - 公司正在调查Jynneos疫苗免疫原性试验中自愿者产生免疫反应的较低比例的原因 [10][11][12] - 公司预计2023年下半年将向美国国家战略储备库交付约1.13亿美元的口服TPOXX,并从其他国内外客户获得3000万至4500万美元的收入 [5][21] - 公司预计2023年全年税前经营利润将达9000万至1亿美元,较上年大幅增长 [6][22] 问答环节重要的提问和回答 问题1 **Pooya Hemami 提问** 是否有进一步讨论19C BARDA合同下的增量订单或2024年之后的储备? [32] **Phil Gomez 回答** 公司正在与美国政府就下一阶段合同进行讨论,目标是在现有合同选项执行完毕后获得TPOXX重新供应的合同 [33][34] 问题2 **Pooya Hemami 提问** PEP入组研究的免疫原性数据与预期不同,会如何影响时间进度或标签扩展? [38] **Phil Gomez 回答** 公司正在更详细地分析免疫原性研究的统计数据,这可能会比预期稍晚一些,但公司正在并行准备提交申请 [39][40] 问题3 **Scott Sibley 提问** 公司是否计划进一步回购股票? [43] **Dan Luckshire 回答** 现有回购计划还有2100万美元额度,公司会与董事会讨论后续步骤 [47]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ Commission File No. 0-23047 SIGA Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 13-38 ...